0.41 | 2.72%
| Price and Volume | |
|---|---|
| Recent Price | 15.46 |
| 52 Week High | 24.06 |
| 52 Week Low | 14.83 |
| Avg. Daily Vol. (Mil) | 0.52 |
| Beta (3 year) | 0.87 |
| Share Related Items | |
| Mkt Cap (Mil) | 868.68 |
| Shares Out (Mil) | 56.19 |
| Float (Mil) | 43.57 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 4.90 |
| LT Debt/ Equity | 0.29 |
| Total Debt / Equity | 0.29 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.88 |
| Price/Book | 5.72 |
| Price/Cash Flow | 336.60 |
| Per Share Data | |
| Earnings | -0.37 |
| Sales | 3.98 |
| Book Value | 2.70 |
| Cash Flow | 0.05 |
| Business Summary | |
|---|---|
| NxStage Medical, Inc, is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. | |
| General Information | |
| 439 South Union Street
5th Floor Lawrence, MA 01843 |
|
| www.nxstage.com | |
| Industry : Health Services | |
| Sector: Health Care | |
| Employees: 2500 | |
| CEO: Jeffrey H. Burbank | |
| Short Interest | |
| Current Month (Mil) | 7.55 |
| Previous Month (Mil) | 6.90 |
| Short Interest Ratio (Days) | 12.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -6.90 |
| Return on Investments | -10.00 |
| Profitability | |
| Gross Margin | 46.50 |
| EBIT Margin | -6.60 |
| Profit Margin | -9.20 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet